NCT05305222View on ClinicalTrials.gov

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

June 15, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab

Intravenous (IV) Infusion

DRUG

Placebo

Intravenous (IV) Infusion

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc /ID# 164197, Cypress

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY